O4 Development and validation of dimethylarginines (DAS) as a novel biomarker to identify pre-ACLF and predict outcomes following acute decompensation of cirrhosis in two prospective multicentre European cohorts

Le résumé fourni par la source

Background and Aims Asymmetric dimethylarginine (ADMA) and its stereoisomer symmetric dimethylarginine (SDMA) reduce nitric oxide generation, cause endothelial cell dysfunction and play a role in driving portal hypertension and liver-related mortality. This study aimed to develop and validate a new scoring system termed DAS, combining these 2 biomarkers, in predicting liver-related events following AD. Method The derivation cohort encompassed patients from the DASIMAR study (n=271), a prospective, observational, UK study recruiting patients admitted non-electively with AD cirrhosis. The validation cohort was from the PREDICT study (n=409) which was a multicentre European trial with a similar design. ADMA and SDMA analysis were performed by liquid chromatography- tandem mass spectrometry at baseline (T0) and a second time point within 7 days (T1). Results With regards to inpatient transplant-free mortality in the DASIMAR cohort, T0 DAS was significantly higher in those who died (13%) compared to survivors (6.2 vs 4.1 umol/L, p<0.001). Indeed, T0 DAS remained a predictor of inpatient mortality in multivariable analysis (OR 1.19 [95% CI 1.03–1.38], p=0.017) and was superior to the baseline CLIF-C AD score. When assessing 90-day mortality, T0 DAS was also significantly higher in those who died (n=63) compared to survivors (5.4 vs 4.1 umol/L, p<0.001). T0 DAS also remained significant in multivariable analysis (OR 1.27 [95% CI 1.08–1.48], p=0.003) and was again superior to the baseline CLIF-C AD score. When assessing 90-day mortality in the PREDICT cohort a similar signal was demonstrated with significantly higher T0 DAS scores in those who died (5.5 vs 4.2 umol/L, p=0.033). Significantly higher T0 DAS scores were noted in the DASIMAR cohort in the pre-ACLF patients (5.4 vs 3.7 umol/L, p=0.002). This was confirmed in the PREDICT cohort where T0 DAS was an independent predictor of ACLF development in multivariable analysis (OR 1.13 [95% CI 1.01–1.25], p=0.027). T0 DAS scores were also significantly higher in those who developed acute kidney injury (AKI) during admission compared to those who did not in the DASIMAR cohort (5.0 vs 3.5 umol/L, p<0.001). This was shown in multivariable analysis (OR 1.24 [1.03 – 1.49], p=0.021) and replicated in the PREDICT cohort where T0 DAS also predicted renal failure in multivariable analysis (OR 1.15 [1.02–1.32], p=0.025). Conclusion This study demonstrates that the novel DAS score can predict liver-related events including mortality, ACLF development and renal dysfunction. With further validation, DAS could be translated for clinical use in identifying patients at risk of liver-related events.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.